BioVie shares plunge as Parkinson’s trial results lack primary motor data

BioVie reported results of its Phase 2 SUNRISE-PD study in early‑stage Parkinson’s disease. The double‑blind, placebo‑controlled trial enrolled 57 patients who had not yet received carbidopa/levodopa. The drug tested, bezisterim (formerly NE3107), is an oral small molecule designed to cross the blood‑brain barrier.

The company described the study as a success based on a combined analysis of motor and non‑motor symptom improvements, but it did not present data for the primary endpoint that measures motor function. Executives called the findings exploratory and said they will help shape the design of a future Phase 3 trial.

Investors reacted sharply, sending BioVie’s shares down nearly 50% to around $1 after the announcement. The steep decline reflected market concerns about the lack of clear primary outcome data.